Search

Breast cancer is among the deadliest gynecology cancers in the world. However, the management of advanced-stage breast cancer is often harder as a result of chemoresistance. This review aimed to discover the effect of bromocriptine on prolactin-positive breast cancer patients who received anthracycline-based chemotherapy. It is known that anthracycline works by inhibiting topoisomerase IIα (TOP2A), forming free radicals, binding DNA, and altering cell homeostasis, hence stopping the cell cycle and inducing cell death. However, reduction of TOP2A expression and increased glutathione s-transferase (GST) and ATP-binding cassette (ATP) membrane activity increase anthracycline efflux from the cell membrane, hence reducing its effectivity. Prolactin is one of the most common chemoresistance agents whose complex with its receptor will induce JAK/STAT pathway to increase GST. The regulation of Bcl-2 and ERK was also determined by prolactin. Bromocriptine is an agonist of the D2 dopamine receptor that inhibits adenyl cyclase and a D1 dopamine weak antagonist. Bromocriptine could reduce prolactin serum and receptors in various cases. Some studies have found that bromocriptine could improve the effectiveness of chemotherapy regimens, including cancer-related hyperprolactinemia, breast cancer that underwent cisplatin, and taxanes. Therefore, bromocriptine offers potential as it could improve outcomes and reduce resistance in prolactin-positive breast cancer patients who are administered anthracycline-based neoadjuvant chemotherapy.

Abstract Promotion is processing satisfaction giving to consumer to get profit. Sensible promotion become determinant success of every small or big company, orientation which profit or nirlaba, domestic and or global. Company management must can plan correctly and can estimate in in all change influence of expense of promotion, general expense, volume of trading and selling price to profit. This research internal issue formula is : 1) Are there influence expense of promotion to profit at Samidi Glass & Craft Gondang, Balance, Sukoharjo ?. 2) Are there general expense influence to profit at Samidi Glass & Craft Sukoharjo ?. 3) Are there volume of trading influence to profit at Samidi Glass & Craft Sukoharjo. Purpose of in this research is: 1) To know influence expense of promotion to profit at Samidi Glass & Craft Sukoharjo. 2) To know general expense influence to profit at Samidi Glass & Craft Sukoharjo. 3) To know volume of trading influence to profit at Samidi Glass & Craft Gondang, Balance, Sukoharjo. Hypothesis submitted is: 1) Anticipated there are influence expense of promotion to profit. 2) Anticipated there are general expense influence to profit. 3) Anticipated there are volume of trading influence to profit. Analyzer applied in this research is Uji Data: Data Normality Test and Uji Linieritas, Hypothesis Test: Parsial Regression Analysis, Regression Analysis Linieritas Berganda, Test Signifikasi: Test t, Test F, Uji R2 ( Coefficient of determination).Based on result of analysed hence inferential : 1) There is influence expense of promotion to profit. 2) there is general expense influence to profit. 3) there is volume of trading influence to profit. Keyword : Expense Of Promotion, General expense, Volume of trading and Profit.

Breast cancer is among the deadliest gynecology cancers in the world. However, the management of advanced-stage breast cancer is often harder as a result of chemoresistance. This review aimed to discover the effect of bromocriptine on prolactin-positive breast cancer patients who received anthracycline-based chemotherapy. It is known that anthracycline works by inhibiting topoisomerase IIα (TOP2A), forming free radicals, binding DNA, and altering cell homeostasis, hence stopping the cell cycle and inducing cell death. However, reduction of TOP2A expression and increased glutathione s-transferase (GST) and ATP-binding cassette (ATP) membrane activity increase anthracycline efflux from the cell membrane, hence reducing its effectivity. Prolactin is one of the most common chemoresistance agents whose complex with its receptor will induce JAK/STAT pathway to increase GST. The regulation of Bcl-2 and ERK was also determined by prolactin. Bromocriptine is an agonist of the D2 dopamine receptor that inhibits adenyl cyclase and a D1 dopamine weak antagonist. Bromocriptine could reduce prolactin serum and receptors in various cases. Some studies have found that bromocriptine could improve the effectiveness of chemotherapy regimens, including cancer-related hyperprolactinemia, breast cancer that underwent cisplatin, and taxanes. Therefore, bromocriptine offers potential as it could improve outcomes and reduce resistance in prolactin-positive breast cancer patients who are administered anthracycline-based neoadjuvant chemotherapy.